PMID- 31539622
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20221207
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 46
IP  - 2
DP  - 2020 Apr
TI  - Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 
      1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes 
      (SUSTAIN 10).
PG  - 100-109
LID - S1262-3636(19)30132-6 [pii]
LID - 10.1016/j.diabet.2019.101117 [doi]
AB  - AIMS: SUSTAIN 10 compared the efficacy and safety of the anticipated most 
      frequent semaglutide dose (1.0mg) with the current most frequently prescribed 
      liraglutide dose in Europe (1.2mg), reflecting clinical practice. METHODS: In 
      this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA(1c) 
      7.0-11.0%) on 1-3 oral antidiabetic drugs were randomized 1:1 to subcutaneous 
      once-weekly semaglutide 1.0mg or subcutaneous once-daily liraglutide 1.2mg. 
      Primary and confirmatory secondary endpoints were changes in HbA(1c) and body 
      weight from baseline to week 30, respectively. RESULTS: Mean HbA(1c) (baseline 
      8.2%) decreased by 1.7% with semaglutide and 1.0% with liraglutide (estimated 
      treatment difference [ETD] -0.69%; 95% confidence interval [CI] -0.82 to -0.56, 
      P<0.0001). Mean body weight (baseline 96.9kg) decreased by 5.8kg with semaglutide 
      and 1.9kg with liraglutide (ETD -3.83kg; 95% CI -4.57 to -3.09, P<0.0001). The 
      proportions of subjects achieving glycaemic targets of<7.0% and=6.5%, weight loss 
      of=5% and=10%, and a composite endpoint of HbA(1c)<7.0% without severe or blood 
      glucose-confirmed symptomatic hypoglycaemia and no weight gain were greater with 
      semaglutide vs liraglutide (all P<0.0001). Both treatments had similar safety 
      profiles, except for more frequent gastrointestinal disorders (the most common 
      adverse events [AEs]) and AEs leading to premature treatment discontinuation with 
      semaglutide vs liraglutide (43.9% vs 38.3% and 11.4% vs 6.6%, respectively). 
      CONCLUSION: Semaglutide was superior to liraglutide in reducing HbA(1c) and body 
      weight. Safety profiles were generally similar, except for higher rates of 
      gastrointestinal AEs with semaglutide vs liraglutide.
CI  - Copyright (c) 2019 Elsevier Masson SAS. All rights reserved.
FAU - Capehorn, M S
AU  - Capehorn MS
AD  - Rotherham Institute for Obesity, Clifton Medical Centre, S65 1DA Rotherham, South 
      Yorkshire, UK. Electronic address: mcapehorn@yahoo.co.uk.
FAU - Catarig, A-M
AU  - Catarig AM
AD  - Novo Nordisk A/S, DK-2860 Soborg, Denmark.
FAU - Furberg, J K
AU  - Furberg JK
AD  - Novo Nordisk A/S, DK-2860 Soborg, Denmark.
FAU - Janez, A
AU  - Janez A
AD  - Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical 
      Centre Ljubljana, 1000 Ljubljana, Slovenia.
FAU - Price, H C
AU  - Price HC
AD  - West Hampshire Community Diabetes Service, SO43 7NG Lyndhurst, UK.
FAU - Tadayon, S
AU  - Tadayon S
AD  - Novo Nordisk A/S, DK-2860 Soborg, Denmark.
FAU - Verges, B
AU  - Verges B
AD  - CHU, 21000 Dijon, France.
FAU - Marre, M
AU  - Marre M
AD  - Clinique Ambroise Pare, 27, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, 
      France.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190917
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
SB  - IM
CIN - Diabetes Metab. 2020 Nov;46(6):515-517. PMID: 31606525
MH  - Administration, Oral
MH  - Aged
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucagon-Like Peptides/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Liraglutide/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Glucagon-like peptide-1 receptor agonist
OT  - Glycaemic control
OT  - Liraglutide
OT  - SUSTAIN
OT  - Semaglutide
OT  - Type 2 diabetes
EDAT- 2019/09/21 06:00
MHDA- 2021/07/08 06:00
CRDT- 2019/09/21 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2019/08/28 00:00 [revised]
PHST- 2019/09/01 00:00 [accepted]
PHST- 2019/09/21 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2019/09/21 06:00 [entrez]
AID - S1262-3636(19)30132-6 [pii]
AID - 10.1016/j.diabet.2019.101117 [doi]
PST - ppublish
SO  - Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 
      2019 Sep 17.